Background: Fetal growth abnormalities in hypoplastic left heart syndrome (HLHS) have been documented primarily by birth measurements. Fetal growth trajectory has not been described. We hypothesized that fetal growth trajectory declines across late gestation in this population. Methods: Infants with a prenatal diagnosis of HLHS and no history of prematurity or a genetic syndrome were identified. Fetal ultrasound measurements and birth anthropometrics were obtained from clinical records. z-Scores for estimated fetal weight (EFWz) and birth weight (BWTz) were compared. BWTz for three neonatal standards were compared. results: Paired fetal and neonatal data were identified in 33 cases of HLHS. Mean gestational age at ultrasound and birth were 27 and 38 wk, respectively. BWTz was lower than EFWz by a mean of 0.82 (SD: 0.72, P < 0.0001), with 64% of subjects demonstrating a decrease in z-score of >0.5. Umbilical artery (UA) Doppler found no evidence of significant placental insufficiency. Modest differences in BWTz were seen across BWT standards in this cohort. conclusion: The majority of fetuses with HLHS demonstrate decreased growth velocity during later pregnancy, suggesting growth abnormalities manifest in utero. The potential relationship to future clinical outcomes warrants further study.
B
irth weight (BWT) is a critical predictor of outcome in infants with cardiovascular malformations (CVMs), especially those with hypoplastic left heart syndrome (HLHS). Infants who are either small for gestational age (<10th percentile) or low BWT (<2.5 kg) are at greater risk of death and complications following cardiac surgery (1, 2) . Such infants also appear to be at greater risk of the long-term neurodevelopmental morbidities that are increasingly apparent in survivors (3). Unfortunately, the incidence of low BWT appears to be greater in infants with HLHS as compared with the general population (4) . This observation is complicated by the association between CVM and prematurity (5) . Fetal somatic growth in this population is poorly understood.
BWT is a complex multifactorial trait that is influenced by genetic (6, 7) and environmental factors (8) . As a single measurement in time, it is a useful summary of the fetal growth preceding delivery. The relationship between growth and clinical outcomes can be further refined through an understanding of the pattern or trajectory of intrauterine growth across gestation (9) . Serial measurements, obtained noninvasively by ultrasound, may be used to identify differential growth patterns, which may influence both short and long-term clinical outcomes (10) . These patterns have not been described in the fetus with HLHS.
The fetal growth standards used for clinical assessment of the pregnancy also refine the interpretation of BWT as a clinical and research outcome. Such standards have been described using two methods: computational estimates derived from ultrasound measurements (11, 12) and direct measurement of live-born infants across the range of viable gestational ages (13) (14) (15) . Both approaches highlight that gestational age is a major determinant of growth and therefore adjust for gestational age when establishing norms. By contrast, standards from the Centers for Disease Control and Prevention (CDC) (16) and the World Health Organization (WHO) (17) were designed to assess BWT and growth in healthy term infants (born 37-42 wk gestation) and children, and therefore do not adjust for gestational age. These distinctions may be important in populations with high rates of prematurity and growth restriction, such as infants with HLHS. Different standards of fetal growth have not been compared in individuals with CVMs.
As such, the aims of this study are (i) to determine fetal growth trajectory in subjects with HLHS, (ii) to determine the proportion of HLHS subjects who demonstrate poor somatic growth in utero, and (iii) to compare different reference standards at both fetal and neonatal time points. We hypothesize that the fetus with HLHS will demonstrate a decreasing growth trajectory from midgestation to birth and that the magnitude of the decline will be influenced by the standard used.
RESULTS

Study Population
A fetal diagnosis of HLHS, fetal biometry measurements, and postnatal birth anthropometrics were available in 33 cases. Characteristics of the cohort are summarized in Table 1 .
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Trajectory of Weight z-Score Decreases From Fetal Ultrasound to Birth
Fetal biometry was measured at a median of 27 wk gestation whereas neonatal anthropometrics were measured at a median of 38 wk. Using the Olsen standard for both measurements, gestational age-adjusted z-score for BWT (BWTz) was lower than gestational age-adjusted z-score for estimated fetal weight (EFWz) by a mean of 0.82 (SD: 0.72, P < 0.0001, Figure 1) . The change in z-score between time points was not associated with gestational age at ultrasound (r: −0.22, P = 0.21) or the duration of time between studies (r: 0.22, P = 0.21). However, using the Hadlock standard for EFWz and the Olsen standard for BWTz showed that BWTz was significantly lower than EFWz by a mean of 0.32 (SD: 0.73, P = 0.02).
The Majority of Subjects Demonstrate Poor Fetal Growth In Utero
Poor fetal growth, as defined by a decrease of ≥0.5 between EFWz and BWTz, was seen in 64% of subjects. Only 6% (two subjects) demonstrated a BWTz that was greater than the EFWz. Umbilical artery (UA) Doppler resistance index was available in 19 of 33 cases, and no evidence of placental insufficiency was identified in those cases, suggesting normal maternal health and adequate nutritional status.
Gestational Age-Adjusted Standards Differ When Based on Fetal Ultrasound Measurements Vs. Neonatal Anthropometrics
The EFWz calculated by the Olsen standard was significantly increased as compared with EFWz calculated by the Hadlock standard (mean: 0.51, P = 0.0014). The Bland-Altman plot demonstrates that the majority of fetuses had a lower EFWz as calculated by the Hadlock method (Figure 2) . 
HLHS fetal somatic growth trajectory
Articles DISCUSSION This study demonstrates that growth trajectory declines from midgestation to birth in the fetus with HLHS. A threshold decrease in z-score of ≥0.5 identified poor growth in 64% of subjects. Of note, the choice of growth standard can influence the magnitude, although not the direction, of these findings. The growth abnormalities in the fetuses with HLHS result in a population of neonates who are, on average, smaller than expected for gestational age and may have growth abnormalities in the context of even "normal" BWT. Given the importance of BWT (1,2) and gestational age (18, 19) as predictors of clinical outcome in CVMs, the observation is important. However, the fetal growth patterns underlying these BWT observations are largely unknown and may influence shortand long-term neurodevelopmental outcomes (10) . Both somatic growth and brain growth (20, 21) may be adversely effected in HLHS. These findings likely make important contributions to the neurodevelopmental outcomes that are now a major focus of the field (22) .
The observation of a declining growth trajectory in later pregnancy may suggest a suboptimal energy balance. Although the available UA resistance index results did not identify definitive placental insufficiency, vascular pathology in the placenta could lead to reduced substrate delivery that is not detectable by current clinical testing. It is also possible that, despite oxygen delivery via the maternal-fetal circulation and compensatory mechanisms within the central nervous system (23), the fetus with HLHS is subject to metabolic inefficiencies of hypoxia, particularly in the brain (24) . Cerebral hypoxia is one potential explanation for the well-described reduction in head and brain size associated with HLHS and may contribute to subsequent adverse clinical outcomes (25) .
An improved understanding of fetal growth trajectory may also facilitate clinical decision making by the medical team that is monitoring the pregnancy. These results inform antenatal testing in the nearly 75% of HLHS cases that are identified by prenatal diagnosis. It appears that some decline in growth trajectory occurs in the vast majority of fetuses with HLHS. For a given fetus with HLHS and decelerating growth on ultrasound, the observation may not confer the same risk of fetal death as primary placental pathology. Given the apparent benefits of even small increases in BWT and gestational age in the neonate with HLHS, the risk-benefit balance of scheduled deliveries favors waiting until at least 39, if not 40 wk. In addition, a closer inspection of placental pathology and growth abnormalities is warranted.
The importance of methodology and reference standards is critical to understanding the magnitude of the growth problem (26) . Differences between ultrasound measurements of the fetus in utero and measurements of the live-born premature infant are well described (27) . These differences appear to vary when there is suspected macrosomia or growth restriction (28) . To date, there are no standards that reconcile high-quality ultrasound measures with neonatal anthropometric reference values in the same population. Our findings of reduced growth velocity persist with all three standards examined in this study. However, it should be noted that the observation of decreased growth trajectory is attenuated when the EFW is referenced to ultrasound standard values. Researchers should be aware of these differences when categorizing BWT in neonates with CVMs.
The recent introduction of WHO growth standards may result in reclassification of some infants who are at the lower end of the growth curve ("low normal" to small for gestational age). There are several methodological differences between the WHO and CDC standards (26) . These differences include characteristics of the population, intervals of measurement, and statistical analyses. Differences may be magnified at the lower BWTs that are common in HLHS. Furthermore, the lower gestational age of many newborns with HLHS must be considered. The Olsen standard was specifically chosen to incorporate gestational age. These differences were most apparent when comparing Olsen values to the CDC standard values. Our cohort suggests that the WHO and Olsen standards function quite similarly for neonates born at 37 wk gestation or greater with HLHS. . The Bland-Altman plot shows the difference between the z-scores from the two standards against the average of the z-scores from the two standards. The solid horizontal line corresponds to the zero difference between the z-scores from the two standards, which is the ideal situation. The three dashed horizontal lines are the actual mean differences between the z-scores (middle dashed line) and 1.96 times the SDs from the mean difference (upper and lower dashed lines). EFWz, z-score for estimated fetal weight. 
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This study has several limitations. The cohort probably represents a "best-case scenario" for patients with HLHS because high-risk subsets were excluded. This may limit the generalizability of the findings. However, by excluding premature infants and infants with genetic syndromes, the cohort allows for an assessment of fetal growth pattern that attempts to isolate the role of structural heart disease while minimizing the confounding influences of maternal disease and extracardiac anomalies. In addition, all ultrasound measurements were obtained during routine clinical care. The variability of such measurements may influence the results but would likely underestimate the true differences, therefore minimizing the risk of a type I error. Assessment of placental function was limited to UA Doppler in a subset of the subjects. More detailed assessment of fetal and uterine flow patterns may provide further insights. Finally, the cohort is underpowered to perform subgroup comparisons such as between HLHS phenotypes (e.g., aortic stenosis vs. aortic atresia).
In summary, a large proportion of fetuses with HLHS demonstrate decreased growth velocity during later pregnancy, which appears unrelated to placental function. The resulting lower BWTs in this population illustrate the importance of using gestational age-adjusted reference standards. Our results provide evidence that growth problems associated with HLHS manifest in utero and warrant careful examination of somatic growth in the fetus. Elucidating different patterns of fetal growth in HLHS may inform outcomes and create opportunities for new prenatal therapies.
METHODS
Study Population
Infants born following prenatal diagnosis of HLHS between January 1998 and June 2010 were identified from databases within the Heart Institute at Cincinnati Children's Hospital Medical Center. HLHS was strictly defined as atresia or stenosis of the aortic and mitral valves, and hypoplasia of the left ventricle and ascending aorta (21) . All patients had intact ventricular septa and normally related great arteries. Exclusion criteria included known genetic syndromes (e.g., Turner Syndrome), prematurity (<37 wk gestation), and multiple-gestation pregnancies. The institutional review board at Cincinnati Children's Hospital Medical Center approved this study with waiver of consent for the collection of de-identified data from existing medical records. 
